Auris Medical Holding AG IPO on NASDAQ
Auris Medical Holding AG (NASDAQ: EARS), a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, conducted its initial public offering (IPO) on the NASDAQ Global Select Market. Auris Medical Holding AG issued a total of 10'113'235 new shares in the offering (including over-allotment option) at a price of USD 6.00 per share.
FRORIEP acted as Swiss legal counsel to Auris Medical Holding AG in the IPO and in the previous corporate re-organization. The FRORIEP team was lead by partner Marco A. Rizzi (Capital Markets and Corporate & Commercial) and included Ansgar Schott (partner, Capital Markets), Alessandro Celli (partner, Intellectual Property), Nicola Benz (partner, Intellectual Property), Dimitri Rotter (partner, Tax), Cyrill Littmann (associate, Corporate & Commercial and Capital Markets), Evelien Zemp (associate, Notarial Services) and Lukas Wadsack (associate, Tax).